Allergy Medicine

Study findings from G.W. Canonica et al broaden understanding of rhinoconjunctivitis

Allergy Medicine Library Library Home This article was published in Disease Prevention Week, which you can subscribe to online.

"Standard care only provides symptoms relief, while allergen specific immunotherapy (SIT) treats the underlying cause of the disease. Grazax((R)) from ALK-Abello is a new, tablet-based, effective route of SIT for home treatment. The objective was to assess the cost-effectiveness of Grazax((R)) in four Southern European countries A prospective pharmacoeconomic analyses was carried out alongside a multinational, clinical trial measuring the efficacy of Grazax((R)). Pooled data on resource use and health outcomes were collected. A societal perspective was adopted, and the analysis had a nine-year time horizon. The primary outcome measure was quality adjusted life years (QALYs) Grazax((R)) was superior to standard care for all efficacy endpoints, including QALYs gained, and resulted in significantly less use of rescue medication and fewer hours missed from work. Grazax((R)) was cost-effective for all countries for an annual price in the range of is an element of 1500-is an element of 1900," wrote G.W. Canonica and colleagues.

The researchers concluded: "The result was improved by inclusion of future costs of asthma and exclusion of Spanish trial centers which experienced an exceptionally low pollen season The analysis illustrates that allergen SIT with Grazax((R)) for grass pollen induced rhinoconjunctivitis is a cost-effective intervention in Southern Europe."

Canonica and colleagues published their study in Respiratory Medicine (Cost-effectiveness of GRAZAX(R) for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe. Respiratory Medicine, 2007;101(9):1885-1894).

For additional information, contact P.B. Poulsen, MUUSMANN Research & Consulting, Haderslevvej 36, DK-6000 Kolding, Denmark.

Publisher contact information for the journal Respiratory Medicine is: W B Saunders Co. Ltd., 32 Jamestown Rd., London NW1 7BY, England.

Keywords: Denmark, Kolding, Allergy Medicine, Rhinoconjunctivitis.

This article was prepared by Disease Prevention Week editors from staff and other reports. Copyright 2007, Disease Prevention Week via NewsRx.com.